Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

Inclusion Criteria: * At least 18 years of age at screening/baseline visit. * Antiretroviral treatment-experienced and have not received any anti-HIV treatment within 12 weeks prior to screening. * Contraceptive use by men or women should be consistent with the local regulations regarding the use of contraceptive methods for subject participating in clinical studies. * Men must agree not to donate sperm during the study until 90 days after receiving the last dose of study drug (or longer, if dictated by local regulations). * Must be able to swallow whole tablets or swallow tablets cut into halves. Exclusion Criteria: * Known active cryptococcal infection, active toxoplasmic encephalitis, Mycobacterium tuberculosis infection, or another AIDS-defining condition that in the judgment of the investigator would increase the risk of morbidity or mortality. * Known resistance to any of the components of D/C/F/TAF; subjects with known or identified FTC resistance attributed to an M184V mutation alone will be permitted to remain in the study. * Prior virologic failure on a DRV-containing regimen from known history or from medical records. * Known history of clinically relevant hepatic disease or hepatitis that in the investigator's judgment is not compatible with D/C/F/TAF. * Known history of severe hepatic impairment as diagnosed based on documented history of severe hepatic impairment (Child-Pugh C). * Known history of chronic (≥3 months) renal insufficiency, defined as having an …